drugset
drugset / Trial / NCT04512170

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects

NCT04512170 ↗

Phase 1 Completed 72 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Safety, Tolerability Pharmacokinetic and Food Effect Study of HEC585 in Healthy Male and Female Subjects

Timeline

Start
2020-07-13
Primary completion
2021-08-23
Completion
2021-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC585 Small molecule 400 mg —

Indications

idiopathic pulmonary fibrosis